Research programme: menorrhagia therapeutics - Arbor Pharmaceuticals

Drug Profile

Research programme: menorrhagia therapeutics - Arbor Pharmaceuticals

Alternative Names: Tranexamic acid prodrug; XP 21510

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator XenoPort
  • Class
  • Mechanism of Action Plasminogen activator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Menorrhagia

Most Recent Events

  • 27 Mar 2012 Suspended - Preclinical for Menorrhagia in USA (PO)
  • 31 Jul 2009 XP 21510 is no longer licensed to Xanodyne Pharmaceuticals in USA
  • 31 Oct 2008 Preclinical development is ongoing for Menorrhagia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top